EUVIMEDEUVIMED entdecken
Beobachtungsstudie

A Pilot Study Describing DOAC Level Results and Association With Clinical Outcomes

Brittni Gochnauer iD, Anne Rodino, Sarah Russell, Kristin Bradley

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900241262363 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Brittni Gochnauer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ambulatory Clinical Pharmacist, The University of Kansas Health System, Kansas City, KS, USA. Hauptthemen laut MEDLINE: Pyridones, Anticoagulants, Pyrazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Describe direct oral anticoagulant (DOAC) level ordering and interpretation practices in association with clinical outcomes at a vascular medicine clinic.

Methods

This study was a retrospective, observational study including patients who had a DOAC level ordered and assessed while on DOAC therapy. The primary outcome was the proportion of DOAC levels within previously reported ranges. Secondary outcomes included thrombotic events, major and clinically relevant non-major bleeding events, and the proportion of DOAC level results which prompted a change in the therapeutic plan.

Results

A total of 43 patients who had a DOAC level ordered while on DOAC therapy were included in the study. More patients were on apixaban than other DOACs, and the most common indication for anticoagulation was deep vein thrombosis (DVT) or pulmonary embolism (PE). The most common reasons for ordering DOAC levels included history of gastric bypass (n = 20) and drug-drug interactions (n = 8). Most patients on apixaban had in-range levels (n = 24) compared to out of-range levels (5 patients). More patients on rivaroxaban had a level out-of-range (n = 10) than in-range (n = 4). One patient had a DVT, resulting in hospitalization and change in DOAC therapy. Two patients had bleeding events, with 1 hospitalization and change in DOAC therapy. DOAC level results also prompted changes in therapeutic plans for 9 of the patients.

Conclusion

DOAC level results did not always correlate with expected outcomes, and further research is warranted to clarify which clinical situations may benefit from ordering DOAC levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesAnticoagulantsPyrazolesHumansPilot ProjectsRetrospective StudiesMaleFemaleAgedMiddle AgedHemorrhageTreatment OutcomeAdministration, OralVenous ThrombosisFactor Xa InhibitorsAged, 80 and overRivaroxabanPulmonary Embolism

Stichwörter der Autor:innen

direct oral anticoagulantdirect oral anticoagulant leveldirect oral anticoagulant monitoringgastric bypassobesity

Substanzen

PyridonesapixabanAnticoagulantsPyrazolesFactor Xa InhibitorsRivaroxaban

Autor:innen und Institutionen

  • Ambulatory Clinical Pharmacist, The University of Kansas Health System, Kansas City, KS, USA.
  • Ambulatory Clinical Pharmacist Practitioner, UNC Health Rex, Raleigh, NC, USA.

ORCID-Profile: Brittni Gochnauer

Zitieren

APA

Gochnauer, B., Rodino, A., Russell, S., & Bradley, K. (2025). A Pilot Study Describing DOAC Level Results and Association With Clinical Outcomes. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241262363

Vancouver

Gochnauer B, Rodino A, Russell S, Bradley K. A Pilot Study Describing DOAC Level Results and Association With Clinical Outcomes. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241262363

BibTeX
@article{Gochnauer2025,
  author = {Gochnauer, Brittni and Rodino, Anne and Russell, Sarah and Bradley, Kristin},
  title = {A Pilot Study Describing DOAC Level Results and Association With Clinical Outcomes},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900241262363}
}
Kostenlos starten →